ArticleBMC ophthalmology2025
Corneal oxidative stress, inflammation, and senescence as key drivers of ocular pathology in a chronic graft-versus-host disease model.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Causal Association Between Commonly Used Medicines and Diabetes-Related Eye Diseases: Univariable and Multivariable Mendelian Randomization Study.Journal of diabetes research · 2026Article
- Ischaemia-Reperfusion Injury in Organ Transplantation: Role of Coenzyme Q10.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic graft-versus-host disease (cGVHD) is a severe complication of allogeneic hematopoietic stem cell transplantation, frequently associated with severe dry eye syndrome. Using a murine cGVHD model, this study investigates the roles of oxidative stress, inflammation, and cellular senescence in corneal damage.
methodsA cGVHD mouse model was established by transplanting bone marrow cells and splenocytes from male C57BL/6J (H-2b) donors into lethally irradiated female BALB/c (H-2d) recipients. Clinical parameters (including survival rates and tear volume), corneal damage(assessed by fluorescein staining score), and ocular tissue inflammation/fibrosis (via histological analysis) were evaluated. Oxidative stress markers (8-OHdG), 4-Hydroxynonenal (4HNE), antioxidant enzymes (catalase), Nuclear factor erythroid 2-related factor 2 (Nrf2), senescence-related genes (P16INK4A, P38 MARK), and inflammation-related proteins (IL6, IL8, NF-κB) were detected using immunohistochemistry (IHC), qPCR, and SA-β-gal staining. Gene Ontology (GO) enrichment analysis was performed to illustrate alterations in gene expression.
resultsChronic ocular GVHD (coGVHD) mice presented with higher clinical scores, characterized by weight loss, skin lesions, and systemic symptoms. They also exhibited reduced tear volume and exacerbated corneal epithelial damage. Histological analysis showed significant inflammation and fibrosis in Meibomian glands (MGs) and lacrimal glands (LGs). Upregulation of 8-OHdG and 4HNE, along with downregulation of catalase and Nrf2, was observed, indicating enhanced oxidative stress and compromised antioxidant defense. Elevated levels of pro-inflammatory markers (IL-6, IL-8, NF-κB), the pro-fibrotic marker α-SMA, and senescence markers (P16INK4A, P38 MARK) were detected. These findings suggest a complex interplay among inflammation, fibrosis, and cellular senescence in the pathogenesis of coGVHD corneas. Bioinformatics analysis revealed significant changes in gene expression related to oxidative stress, inflammation, and senescence in coGVHD corneas.
conclusionThe study elucidates the central roles of oxidative stress, inflammation, and cellular senescence in corneal pathology in cGVHD, identifying potential targets for innovative therapeutic strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.